ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SN. Smith & Nephew Plc

1,122.00
-3.00 (-0.27%)
26 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Smith & Nephew Plc LSE:SN. London Ordinary Share GB0009223206 ORD USD0.20
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.00 -0.27% 1,122.00 1,125.50 1,126.50 1,132.00 1,121.00 1,123.00 3,601,342 16:35:04
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Ortho,prosth,surg Appl,suply 5.55B 263M 0.3008 37.42 9.84B
Smith & Nephew Plc is listed in the Ortho,prosth,surg Appl,suply sector of the London Stock Exchange with ticker SN.. The last closing price for Smith & Nephew was 1,125p. Over the last year, Smith & Nephew shares have traded in a share price range of 887.00p to 1,215.50p.

Smith & Nephew currently has 874,320,227 shares in issue. The market capitalisation of Smith & Nephew is £9.84 billion. Smith & Nephew has a price to earnings ratio (PE ratio) of 37.42.

Smith & Nephew Share Discussion Threads

Showing 976 to 1000 of 1350 messages
Chat Pages: Latest  42  41  40  39  38  37  36  35  34  33  32  31  Older
DateSubjectAuthorDiscuss
09/6/2021
12:16
Credit Suisse upgraded shares of artificial hip and knee maker Smith & Nephew on Wednesday to 'outperform' from 'neutral', lifting the price target to 1,805p from 1,560p as it pointed to "underappreciated growth drivers".The bank argued that S&N is an underappreciated elective surgery recovery play in the near term and that investors underestimate the combined power of recently-acquired growth drivers with corresponding return leverage mid-term.It upped its FY21-23 sales/adjusted earnings per share estimates by an average 2%/6%, leaving it 3%/5% above Bloomberg consensus."As the drivers become clearer gaining the confidence of investors, we expect Smith & Nephew stock to reverse its material underperformance over the past 12 months," Credit Suisse said.The bank noted that since late 2017, Smith & Nephew has bought several bolt-on technologies, committing close to $1.6bn, and with associated negative M&A effects on trading margin of around 150 basis points for FY21."We deep-dived into the potential for the new technologies," it said. "We believe the Wound Biologics/Sports Medicine/Extremities/ENT franchises can add circa 80/15/40/40bps to group underlying growth mid-term."This would turn Smith & Nephew from low-to-mid single digit into mid-to-high single digit underlying growth mode and generate relevant operating leverage, providing upside to trading margin."
1nf3rn0
09/6/2021
09:49
CREDIT SUISSE RAISES SMITH & NEPHEW TO 'OUTPERFORM' (NEUTRAL) - TARGET 1,805 (1,560) PENCE
its the oxman
09/6/2021
08:27
Fall was unjustified, their main markets are virtually back to normal and lots of pent up demand. Perhaps broker highlighting this?
spoole5
09/6/2021
08:17
Bouncing back today, any reason?
its the oxman
09/6/2021
08:01
I was referencing his opinion on pe as a valuation method
spoole5
08/6/2021
22:13
Terry holds Stryker, from memory. Not SN as far as I'm aware.
essentialinvestor
08/6/2021
21:43
Ask terry smith what he thinks of pe
spoole5
08/6/2021
18:59
Only 27 X FY 2022 earnings, what's not to like, eh )
essentialinvestor
08/6/2021
18:44
Yes US cases are literally down to the hundreds per state.
Down 98% from peak
10,000 for the whole of the USA
Have done better than UK as using just Pfizer and Moderna (few % J&J)
Highly effective

US will have a big boom come 4th July
Less than a month to go now!

justiceforthemany
08/6/2021
17:16
Nice entry point under £14 on an all things being equal basis.
essentialinvestor
08/6/2021
17:14
May retest the 1350 lows.
spoole5
05/6/2021
08:44
Needs to climb through c.1600p to break clear of its downward channel from all time high.
its the oxman
19/5/2021
08:38
The us is virtually back to normal, where this company does most of its business, yet it still languishes
spoole5
10/5/2021
18:27
Taken out the most likely scenario.
spoole5
08/5/2021
22:33
Steady climb back to 2000p as covid recedes, operations pick up , or we get taken out.
its the oxman
29/4/2021
16:35
Added today expecting further gains / market catch up , on the back of this well received update.
its the oxman
29/4/2021
07:45
Looks decent, probably the only covid sensitive stock yet to recover!
spoole5
29/4/2021
07:36
Very encouraging trading statement. May well see that target price of £19.85 before too long...
hubshank
21/4/2021
19:21
Health care stocks have outperformed, due to a positive read across from US medical devices company Intuitive Surgical, which has sent Smith and Nephew shares to two-month highs,” said CMC Markets analyst Michael Hewson.

ADVFN Marke report.

philanderer
21/4/2021
15:05
Humongous rally it is then....
timbo_slice
21/4/2021
15:02
Berenberg reiterates buy with a target price of 1,985.0p
philanderer
19/4/2021
16:21
Must be correctly priced then.... or due a humongous rally....
timbo_slice
19/4/2021
10:27
Everything apart from this seems to be pricing in the reopening of economies, even airlines!
spoole5
06/4/2021
20:48
Every little helps! US cracking on with their vaccinations too...
hubshank
06/4/2021
14:26
This is a global organisation, UK a relatively small part of revenue.
essentialinvestor
Chat Pages: Latest  42  41  40  39  38  37  36  35  34  33  32  31  Older

Your Recent History

Delayed Upgrade Clock